PUBLICATION

Global Business Reports

AUTHORS

Catherine Howe, Neha Premjee, Emma Johannes

United States Biopharmaceuticals 2018 Pre-Release

March 15, 2018

A global powerhouse and forerunner on the international stage, the U.S. biopharmaceutical industry is recognized as the most prominent proponent of medical innovation around the world. As the industry moves from treatments towards cures and pipelines are developed around the notion of precision medicine, more and more life-changing therapies are entering the market. With an increasing amount of innovation stemming from small biotechnology companies and university spin-offs, the importance of fostering innovation and providing a supportive framework is paramount. Regional hubs with flourishing innovation ecosystems are notable for the incentives they offer and, as such, have become centers for innovation and knowledge exchange. GBR’s 2018 U.S. Biopharmaceuticals Pre-release shines a spotlight on the Boston/Cambridge area and San Francisco Bay Area as top destinations for investment and biopharmaceutical activity.

RELATED INTERVIEWS MORE INTERVIEWS

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.
Piramal Pharma updates GBR in its recent developments and prospects.
Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.
Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

RECENT PUBLICATIONS

Québec and Atlantic Canada Mining 2025

Québec and Atlantic Canada have traversed 2025 in an enviable position. Strong gold prices have buoyed balance sheets and investor sentiment, while global demand for critical minerals keeps the region firmly on the radar of international markets. At the same time, the provinces’ depth of mining expertise – from AI-driven exploration to advanced drilling, blasting, and geophysics – ensures that technological advantage is firmly on their side.

MORE PREVIOUSLY PUBLISHED

MACIG

"Our jurisdictional diversification is certainly a defining characteristic of Thor, but so is the fact that our projects are also diversified by stage of development."

SUBSCRIBE TO OUR NEWSLETTER